FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2015655380> ?p ?o ?g. }

• W2015655380 endingPage "1053.e4" @default.
• W2015655380 startingPage "1048" @default.
• W2015655380 abstract "To investigate the maximum tolerated dose of ranibizumab administered as a single intravitreal injection.Open-label, 5-center, uncontrolled, prospective, dose-ranging, interventional case series.Twenty-seven patients with subfoveal choroidal neovascularization (CNV) secondary to age-related macular degeneration (AMD) with best-corrected Snellen equivalent visual acuity (VA) of 20/100 or worse and considered ineligible for laser photocoagulation or photodynamic therapy.A single intravitreal injection of ranibizumab was to be administered at 1 of 6 escalating doses (50, 150, 300, 500, 1000, and 2000 microg), with escalation to the next dose level occurring only after the safety and tolerability of the lower dose level was established through postinjection day 14. Follow-up examinations were performed on postinjection days 1, 3, 7, 14, 42, and 90. Enrollment was stopped if > or =2 patients experienced dose-limiting toxicity.The primary safety measures were changes from baseline in VA, intraocular pressure (IOP), intraocular inflammation, and production of antiranibizumab antibody. Dose-limiting toxicity was defined by intraocular inflammation, elevated IOP, reduced VA, or hemorrhage within 90 days after injection.All patients completed this single intravitreal injection study, and 500 microg of ranibizumab was the maximum tolerated dose. At the higher dose of 1000 microg, significant intraocular inflammation was noted. All adverse events were self-limited, and no infectious endophthalmitis occurred. Aqueous or vitreous ocular inflammation occurred in 12 subjects, with complete resolution within 42 days. In 9 of the subjects, the inflammation was graded as trace to 1+ and required no treatment; in 3 of the subjects, the inflammation was graded as 2+ or 3+, and 2 of the 3 were treated with topical 1% prednisolone acetate. No serum antiranibizumab antibodies were detected. All patients had VA similar or improved compared with baseline values.The maximum tolerated single dose of ranibizumab in neovascular AMD patients was 500 microg. Single intravitreal injections of ranibizumab up to a dose of 500 microg were safe and well tolerated in this small group of patients." @default.
• W2015655380 created "2016-06-24" @default.
• W2015655380 creator A5003170725 @default.
• W2015655380 creator A5046713073 @default.
• W2015655380 creator A5048392799 @default.
• W2015655380 creator A5055379155 @default.
• W2015655380 creator A5062102495 @default.
• W2015655380 creator A5068100425 @default.
• W2015655380 creator A5079231031 @default.
• W2015655380 creator A5087700840 @default.
• W2015655380 date "2005-06-01" @default.
• W2015655380 modified "2023-09-23" @default.
• W2015655380 title "Maximum Tolerated Dose of a Humanized Anti–Vascular Endothelial Growth Factor Antibody Fragment for Treating Neovascular Age-Related Macular Degeneration" @default.
• W2015655380 cites W109974915 @default.
• W2015655380 cites W122369139 @default.
• W2015655380 cites W1487528435 @default.
• W2015655380 cites W1601975653 @default.
• W2015655380 cites W1817465123 @default.
• W2015655380 cites W1985712533 @default.
• W2015655380 cites W1998386860 @default.
• W2015655380 cites W2004681222 @default.
• W2015655380 cites W2029111837 @default.
• W2015655380 cites W2035353185 @default.
• W2015655380 cites W2037623358 @default.
• W2015655380 cites W2046507292 @default.
• W2015655380 cites W2051842051 @default.
• W2015655380 cites W2054864390 @default.
• W2015655380 cites W2070049579 @default.
• W2015655380 cites W2075634939 @default.
• W2015655380 cites W2096735172 @default.
• W2015655380 cites W2098155102 @default.
• W2015655380 cites W2098734587 @default.
• W2015655380 cites W2137893922 @default.
• W2015655380 cites W2154200023 @default.
• W2015655380 cites W2157769714 @default.
• W2015655380 cites W2209867202 @default.
• W2015655380 cites W2324588265 @default.
• W2015655380 cites W945208301 @default.
• W2015655380 cites W1601092960 @default.
• W2015655380 cites W981629403 @default.
• W2015655380 doi "https://doi.org/10.1016/j.ophtha.2005.01.043" @default.
• W2015655380 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/15885778" @default.
• W2015655380 hasPublicationYear "2005" @default.
• W2015655380 type Work @default.
• W2015655380 sameAs 2015655380 @default.
• W2015655380 citedByCount "212" @default.
• W2015655380 countsByYear W20156553802012 @default.
• W2015655380 countsByYear W20156553802013 @default.
• W2015655380 countsByYear W20156553802014 @default.
• W2015655380 countsByYear W20156553802015 @default.
• W2015655380 countsByYear W20156553802016 @default.
• W2015655380 countsByYear W20156553802017 @default.
• W2015655380 countsByYear W20156553802018 @default.
• W2015655380 countsByYear W20156553802019 @default.
• W2015655380 countsByYear W20156553802020 @default.
• W2015655380 countsByYear W20156553802021 @default.
• W2015655380 countsByYear W20156553802023 @default.
• W2015655380 crossrefType "journal-article" @default.
• W2015655380 hasAuthorship W2015655380A5003170725 @default.
• W2015655380 hasAuthorship W2015655380A5046713073 @default.
• W2015655380 hasAuthorship W2015655380A5048392799 @default.
• W2015655380 hasAuthorship W2015655380A5055379155 @default.
• W2015655380 hasAuthorship W2015655380A5062102495 @default.
• W2015655380 hasAuthorship W2015655380A5068100425 @default.
• W2015655380 hasAuthorship W2015655380A5079231031 @default.
• W2015655380 hasAuthorship W2015655380A5087700840 @default.
• W2015655380 hasConcept C118487528 @default.
• W2015655380 hasConcept C126322002 @default.
• W2015655380 hasConcept C141071460 @default.
• W2015655380 hasConcept C197934379 @default.
• W2015655380 hasConcept C2776403814 @default.
• W2015655380 hasConcept C2776694085 @default.
• W2015655380 hasConcept C2777235844 @default.
• W2015655380 hasConcept C2777802072 @default.
• W2015655380 hasConcept C2778257484 @default.
• W2015655380 hasConcept C2778375690 @default.
• W2015655380 hasConcept C2781092963 @default.
• W2015655380 hasConcept C2781100027 @default.
• W2015655380 hasConcept C2781359195 @default.
• W2015655380 hasConcept C29730261 @default.
• W2015655380 hasConcept C71924100 @default.
• W2015655380 hasConceptScore W2015655380C118487528 @default.
• W2015655380 hasConceptScore W2015655380C126322002 @default.
• W2015655380 hasConceptScore W2015655380C141071460 @default.
• W2015655380 hasConceptScore W2015655380C197934379 @default.
• W2015655380 hasConceptScore W2015655380C2776403814 @default.
• W2015655380 hasConceptScore W2015655380C2776694085 @default.
• W2015655380 hasConceptScore W2015655380C2777235844 @default.
• W2015655380 hasConceptScore W2015655380C2777802072 @default.
• W2015655380 hasConceptScore W2015655380C2778257484 @default.
• W2015655380 hasConceptScore W2015655380C2778375690 @default.
• W2015655380 hasConceptScore W2015655380C2781092963 @default.
• W2015655380 hasConceptScore W2015655380C2781100027 @default.
• W2015655380 hasConceptScore W2015655380C2781359195 @default.
• W2015655380 hasConceptScore W2015655380C29730261 @default.
• W2015655380 hasConceptScore W2015655380C71924100 @default.
• W2015655380 hasIssue "6" @default.
• W2015655380 hasLocation W20156553801 @default.

• next